For uterine cancer, the markers that matter most come from the tumor itself, tested in tissue removed at biopsy or surgery rather than from a blood draw. Those results often appear on the pathology report and can shape both the treatment plan and the expected outlook.1PubMed. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series Blood markers such as CA-125 and HE4 do exist, but none of them can diagnose uterine cancer by itself, and their main job is watching for a return after treatment.
The Four Molecular Groups That Shape Treatment
A simple step-by-step tissue test places every endometrial cancer into one of four groups, and each group has its own survival outlook.2PubMed. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer This grouping predicts outcomes better than the older risk systems, which rely mainly on how the tumor looks and how far it has spread.3PubMed. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer The test can be run on the biopsy taken at diagnosis, so the result can help decide how much surgery is needed and whether extra treatment follows.4PubMed. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series The four groups are POLE-mutated, mismatch repair (MMR) deficient, p53-abnormal, and a group with none of these changes.
POLE is a gene the cell uses to copy its DNA accurately, and a fault in it creates a distinct type of tumor.5PubMed Central. The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review These tumors carry very large numbers of mutations and draw in many immune cells, and they tend to do well.6PubMed Central. The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review Even when they look high-grade under the microscope, POLE-mutated tumors carry roughly a third of the risk of death and of the cancer growing, compared with similar tumors without the mutation.7PubMed Central. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis Because of that, a POLE-mutated tumor may allow doctors to recommend less additional treatment, which spares some women the side effects of radiation or chemotherapy.
p53 is a protein that normally stops damaged cells from dividing, and an abnormal p53 result is an important warning sign in both serous and endometrioid cancers.8PubMed Central. Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation Abnormal p53 is linked to high-grade tumors, a more advanced stage, and spread to the cervix, ovaries, or tubes.9PubMed Central. Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation About 9 in 10 serous carcinomas, an aggressive uterine cancer type, carry p53 mutations, and the mutations appear early in the tumor’s development.10PubMed Central. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis An abnormal p53 result usually means more intensive treatment and closer follow-up.11PubMed Central. Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation
p53 is usually checked with a stain on the tumor slide rather than a separate genetic test. The report may say “aberrant” or “mutant-type” for an abnormal result and “wild-type” for a normal one. The stain can show either too much p53 or none at all, and both patterns count as abnormal. If the report doesn’t say which group your tumor falls into, ask your doctor.
The group with no specific profile is the most common. Its outlook usually depends on grade, stage, and hormone receptors.
Mismatch Repair Testing and Lynch Syndrome
Mismatch repair proteins fix copying errors in DNA. When one of them is missing, the tumor is called MMR-deficient. MMR testing is used to screen for Lynch syndrome, to predict response to a kind of immunotherapy, and to help estimate outlook.12PubMed Central. Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update This immunotherapy releases a brake on the immune system so it attacks the cancer.13PubMed Central. Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update For advanced or returning cancer, an MMR-deficient tumor makes immunotherapy a stronger option, so it’s worth asking whether your stage makes it relevant now or later.
Lynch syndrome is an inherited condition that raises the risk of uterine, colon, and some other cancers. A deficient result is usually followed by genetic counseling and a blood or saliva test to check whether the change is inherited. If it is, parents, siblings, and children may want testing and earlier cancer screening.
A deficient result doesn’t automatically mean the change is inherited. Many MMR-deficient tumors develop it on their own, when a repair gene is switched off in the tumor. Labs often run an extra test to tell this kind apart from Lynch syndrome, but only a test for an inherited change confirms Lynch syndrome. For genetic counseling, bring a copy of the pathology report showing which MMR proteins were missing, along with your family history of cancers and the ages at diagnosis.
Estrogen and Progesterone Receptors
ER and PR (estrogen and progesterone receptors) are proteins that let a cell respond to those hormones, and the report lists each as positive or negative. About 85 in 100 endometrial cancers are positive for one or both.14PubMed Central. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? The share falls from about 9 in 10 in the common, slower type 1 cancers to about 2 in 3 to 7 in 10 in the aggressive type 2 cancers.15PubMed Central. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?
Tumors that have lost these receptors tend to have a worse outlook.16PubMed Central. Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer—An Immunohistochemical Assessment PR levels are lower in high-grade and advanced tumors than in low-grade, early ones.17PubMed Central. Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer—An Immunohistochemical Assessment Receptor status helps doctors choose who may benefit from hormone therapy, though how well it predicts response is still being confirmed.18PubMed Central. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis
Hormone therapy is usually progestin pills, an IUD that releases progestin, or drugs that block estrogen. It is used for advanced or returning cancer, and sometimes for early cancer in women who want to stay fertile.
On the report, hormone receptors may appear as a percentage of stained cells or an intensity score. “Positive” and “negative” are the key words to look for.
HER2 in Serous Uterine Cancer
HER2 is a growth signal on the cell surface. When a tumor makes too much of it, cancer cells grow faster. About 25 to 30 in 100 serous endometrial carcinomas are HER2-positive, which opens the door to targeted treatment.19PubMed. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand Among p53-abnormal tumors, about 1 in 4 is also HER2-positive.20PubMed Central. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
A positive result can lead to drugs aimed at HER2, such as trastuzumab, added to chemotherapy. If you have serous or p53-abnormal cancer, ask whether HER2 testing was done.
The testing method matters. Genetic sequencing alone finds HER2 extra copies in about 1 in 10 serous tumors and can disagree with standard slide tests.21PubMed Central. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy The usual standard is a slide stain, confirmed by a gene-copy test when the result is borderline.
Slide stains are scored 0 to 3+. A 2+ is borderline and usually needs a second test; a 3+ or confirmed amplification counts as positive.
Blood Tests CA-125 and HE4
CA-125 is a protein measured in a blood draw, reported in units per milliliter (U/mL). After surgery for early endometrial cancer, levels in women whose cancer later returned crept upward, and the difference from women who stayed cancer-free became clear by about 15 to 18 months.22PubMed. To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution At 18 months, a level of about 9.6 U/mL or higher marked women at greater risk of a return.23PubMed. To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution In stage I cancer, a level of about 13.8 U/mL or higher after surgery went with more recurrences, so a check 6 to 12 months after surgery may help.24PubMed Central. The relationship between serum CA-125 level and recurrence in surgical stage I endometrial cancer patients
These cutoffs are well below the 35 U/mL many labs print as the upper normal limit. The trend matters more than a single normal-looking value, and a baseline level soon after treatment makes it easier to read. Repeat tests at the same lab when possible, since methods vary, and bring your results to every visit.
HE4 is another blood protein that tends to be higher in endometrial cancer.25PubMed Central. HE4 as a Biomarker for Endometrial Cancer Higher HE4 is linked to deeper tumor growth and lymph node spread, so it may help plan surgery.26PubMed Central. HE4 as a Biomarker for Endometrial Cancer On its own, though, HE4 tells cancer from non-cancer only moderately well and doesn’t reflect the cancer’s stage or type.27PubMed Central. The diagnostic value of human epididymis protein 4 for endometrial cancer is moderate
Diagnosis still requires a tissue sample from a biopsy or hysteroscopy, and abnormal bleeding after menopause needs a biopsy whatever the blood results. A normal CA-125 doesn’t rule cancer out.
Why CA-125 Can Be High Without Cancer
CA-125 rises with many non-cancer conditions, including endometriosis, so it is less reliable in women who haven’t reached menopause.28PubMed Central. Elevated CA 125 in a CASE of Leaking Endometrioma Some benign gynecologic problems push it above 1,000 U/mL, and endometriosis accounted for nearly half of such cases.29PubMed. Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases A very high number alone doesn’t prove cancer.
Menstruation, pregnancy, fibroids, and pelvic infection can also raise CA-125, as can liver disease and fluid in the abdomen. Tell your doctor about any of these before a result is interpreted.
CA-125 lasts about 6 days in the blood before half of it clears.30PubMed Central. Elevated CA 125 in a CASE of Leaking Endometrioma Retesting too soon after a flare or surgery can therefore still show a high value. After an unexpected high result, doctors usually repeat the test and order imaging rather than act on one number.
Newer Tests Being Studied
ctDNA (circulating tumor DNA) is tiny fragments of tumor DNA in the blood, and testing for it 4 to 8 weeks after surgery may reveal cancer cells too small to see.31PubMed. Circulating tumor DNA in endometrial cancer: clinical significance and implications In stage I uterine cancers, women with detectable tumor DNA after surgery had a recurrence rate above 50 in 100, compared with 6 in 100 or fewer when none was found.32PubMed. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies Few studies compare it directly with CA-125 and HE4, though.33PubMed. Circulating tumor DNA in endometrial cancer: clinical significance and implications
A DNA test on routine Pap test fluid found 81 in 100 endometrial cancers, including 78 in 100 early ones, and flagged only about 1 in 70 women without cancer.34PubMed Central. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers Pap samples found tumor mutations more often than blood did, about 77 versus 43 in 100.35PubMed Central. Evaluation of cell-free DNA from papanicolaou smears and peripheral blood to detect endometrial cancer Chemical tags on certain genes, measured in vaginal swabs from women with bleeding after menopause, picked out early cancers very accurately.36PubMed Central. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development None of these tests is part of standard screening yet.37PubMed Central. Screening Strategies to Improve Early Diagnosis in Endometrial Cancer
Some are offered only in clinical trials, and insurance rarely covers them outside a trial. A trial may be worth asking about if you’re at high risk, for example with Lynch syndrome. A standard Pap test misses most uterine cancers, so report any abnormal bleeding promptly rather than relying on a normal Pap result.
Markers for Uterine Sarcoma
Uterine sarcomas are rare and varied, and no marker is reliable enough for routine diagnosis or outlook.38PubMed Central. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma Leiomyosarcoma, the most common type, often has changes in genes such as TP53, RB1, ATRX, and MED12.39PubMed Central. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma Low-grade and high-grade endometrial stromal sarcomas carry different gene fusions that help the pathologist name the subtype.40PubMed Central. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma Certain tissue stains can help separate leiomyosarcoma from a benign fibroid, and high levels point to a worse outlook.41PubMed Central. Transcriptome profiling of uterine leiomyosarcomas identifies a leiomyoma-like expression pattern that indicates better survival
Telling fibroid from sarcoma is hard because both are muscle tumors and can look alike on scans. CA-125 doesn’t reliably tell them apart. A fibroid that grows after menopause deserves prompt evaluation. For a rare tumor, ask whether a pathologist specializing in sarcoma reviewed the slides.
Questions to Ask About Your Marker Results
Treatment guidelines now build the molecular groups into risk decisions, including whether to remove lymph nodes.42PubMed Central. MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer So ask whether your tumor was tested for POLE, MMR, p53, and hormone receptors. If your cancer is serous or p53-abnormal, ask about HER2. At the treatment visit, useful questions are which group your tumor is in and how that changes your plan, whether your MMR result means you need genetic testing, and whether you’re a candidate for hormone therapy, immunotherapy, or HER2-targeted drugs.
For follow-up, ask whether your team will track CA-125 and how often, and what change in level would prompt a scan. You can also ask whether a tumor DNA blood test or a clinical trial would suit you. Request copies of your pathology and molecular reports and keep them with your blood test results.